沙丁胺醇联合布地奈德治疗哮喘-慢阻肺重叠综合征临床疗效及对患者炎症免疫功能影响观察  

Clinical Eficacy of Salbutamol Combined with Budesonide in the Treatment of Asthma-COPD Overlap Syndrome and its Effect on Inflammatory Immune Function in Patients

作　　者：张晓春[1] 赵品勇 周燕萍[1] 王跃斌[2] 古晓娟 Zhang Xiaochun;Zhao Pinyong;Zhou Yanping;Wang Yuebin;Gu Xiaojuan(Department of Pharmacy,the Second People's Hospital of Yibin City,Sichuan Yibin 644000,China;Department of Pain,the Second People's Hospital of Yibin City,Sichuan Yibin 644000,China;Department of Respiratory Medicine,the Second People's Hospital of Yibin City,Sichuan Yibin 644000,China)

机构地区：[1]宜宾市第二人民医院药学部,四川宜宾644000 [2]宜宾市第二人民医院疼痛科,四川宜宾644000 [3]宜宾市第二人民医院呼吸科,四川宜宾644000

出　　处：《中国药师》2020年第12期2412-2415,共4页China Pharmacist

摘　　要：目的:观察沙丁胺醇联合布地奈德治疗哮喘-慢阻肺重叠综合征(ACOS)的疗效,及对患者血清炎症因子水平与免疫功能的影响。方法:ACOS患者80例随机分为对照组和观察组各40例。对照组在常规治疗基础上加用沙丁胺醇吸入治疗,观察组在常规治疗基础上加用沙丁胺醇联合布地奈德吸入治疗。治疗12周后,比较两组患者治疗前后肺功能情况、哮喘控制测试(ACT评分表)和慢阻肺评估测试评分(CAT)、血清炎症因子(CRP、PCT、IL-6、TNF-α)及免疫指标(Th1和Th1/Th2)的水平变化,观察两组临床疗效和药品不良反应。结果:观察组总有效率为95.0%,显著高于对照组的80.0%(P<0.05)。治疗后,两组患者的FEV1、FEV1/FVC比值和PEF昼夜变异率等肺功能指标,ACT和CAT评分,血清CRP、PCT、IL-6和TNF-α水平,Th1和Th1/Th2水平等指标均较治疗前明显改善(P<0.05),且观察组上述指标均明显优于对照组(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:沙丁胺醇联合布地奈德治疗ACOS疗效好,能显著改善患者肺功能,减轻临床症状,降低炎症因子水平,改善患者免疫功能,且安全性好,值得临床推广使用。Objective: To observe the efficacy of albuterol combined with budesonide in the treatment of asthma-COPD overlap syndrome( ACOS) and its effect on serum inflammatory factors and immune function in patients. Methods: Totally 80 patients with ACOS were randomly divided into control group and observation group with 40 patients in each. The control group was treated with salbutamol inhalation on the basis of the conventional treatment,and the observation group was treated with salbutamol combined with budesonide on the basis of the conventional treatment. After 12 weeks of treatment,the changes in lung function,asthma control test( ACT scale) and COPD assessment test score( CAT),serum inflammatory factors and immune indicators were compared between the two groups before and after the treatment,and the clinical efficacy and adverse drug reactions of the two groups were observed. Results: The total effective rate in the observation group was 95.0%,which was significantly higher than that( 80.0%) in the control group( P<0.05). After the treatment,the lung function indicators such as FEV1,FEV1/FVC ratio and PEF diurnal variation rate,ACT and CAT scores,serum CRP,PCT,IL-6 and TNF-levels,Th1 and Th1/Th2 levels were significantly improved in both groups compared with those before the treatment( P<0.05). The above indices in the observation group were significantly better than those in the control group( P< 0.05). There was no statistically significant difference in the incidence of ADRs between the two groups( P >0.05).Conclusion: Salbutamol combined with budesonide in the treatment of ACOS is effective,which can significantly improve patient’s lung function,reduce clinical symptoms,reduce inflammatory factor levels and improve patient’s immune function with high safety,and is worthy of promotion in clinical use.

关 键 词：沙丁胺醇 布地奈德 哮喘-慢阻肺重叠综合征 炎症因子 免疫功能 

分 类 号：R974.3[医药卫生—药品]